Mechanisms of glucagon-like-peptide 1 in the brain beyond metabolic effects

Article information

Ann Pediatr Endocrinol Metab. 2025;30(4):165-174

Publication date (electronic) : 2025 August 31

doi : https://doi.org/10.6065/apem.2448320.160

Kyu Sik Kim ¹

, Joon Seok Park ¹

, Hyung Jin Choi^,¹^,²^,³^,⁴^,⁵

¹Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea

²Department of Anatomy and Cell Biology, Seoul National University College of Medicine, Seoul, Korea

³Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Korea

⁴Wide River Institute of Immunology, Seoul National University, Hongcheon, Korea

⁵Department of Brain and Cognitive Sciences, Seoul National University, Seoul, Korea

Address for correspondence: Hyung Jin Choi Department of Biomedical Sciences, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea Email: hjchoi@snu.ac.kr

Received 2024 December 26; Revised 2025 January 17; Accepted 2025 January 21.

Abstract

Ever since its discovery, glucagon-like-peptide 1 (GLP-1) and drugs with similar function (collectively GLP-1s) have been used for type 2 diabetes mellitus and have been effective for obesity. Their profound effect on weight loss has resulted in widespread use of these medicines for treating obesity. Extensive studies have shown that GLP-1s decrease body weight, lean mass, and other metabolic phenotypes. These studies were supported by the mechanism of signaling pathways of GLP-1s in cells and their metabolic effects. Recently, studies have focused on the effect of GLP-1s on the brain, showing that they affect food cognition, depression, drug addiction, and even neurodegenerative diseases. Although recent studies have investigated the impact of GLP-1s on the brain, our understanding of these effects is limited. This review describes how GLP-1s have become the most effective drugs in obesity, such as their known signaling pathway in cells and their pharmaceutical processing over the years. This review covers recent discoveries of the GLP-1 mechanisms in the brain, including their prominent effects on obesity, and discusses discoveries that imply their potential usage in brain disorders.

Keywords: Glucagon-like peptide-1; Obesity; Metabolism; Brain disorder; Glucagon-like peptide-1 receptor; Hypothalamus; Hindbrain

Highlights

· Discovery of glucagon-like-peptide 1 (GLP-1) has led to effective treatment of obesity.

· GLP-1 mostly works in the brain by GLP-1 receptors in hypothalamic and brainstem regions in the brain.

· GLP-1 is being developed for use in various diseases outside obesity.

Discovery and clinical applications of GLP-1s

Glucagon-like-peptide 1 (GLP-1) was first discovered about 40 years ago in the early 1980s in the Habener lab, stemming from techniques for cloning anglerfish proglucagon cDNA, which was later used to clone mammalian proglucagon cDNA [1-4] (Fig. 1). Discovery of GLP-1 led to elucidation of their conversion to proglucagon by proprotein convertases such as furin [5,6]. Inspection of the amino acid sequences of GLP-1s revealed that they had 2 equally bioactive forms: glycine-extended GLP-1 (GLP17-37) and amidated GLP-1 (GLP17-36). Soon after, GLP-1 was revealed to be insulinotropic, originating from the intestinal L cells and pancreatic β-cells [6,7]. GLP-1s seemed to be highly related to meal consumption, as their plasma concentration levels were elevated during ingestion of food [8]. However, these proteins were in circulation for only a short time, limited to 1-2 minutes, due to their degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which raised questions regarding use of GLP-1s as pharmaceutical treatments [9]. DPP-4 was first discovered in 1966 and has been shown to circulate to all parts of the body through the plasma [10-12]. As an enzyme, DPP-4 was highly efficient when a substrate had a second amino acid of proline or alanine [12]. As with GLP-1, they had alanine at position 8, which contributed to their short lives during plasma circulation by binding to DPP-4 [9]. This disadvantage was soon mitigated by the discovery of exenatide (Ex-4) in 1992, the first GLP-1 receptor agonist (GLP-1RA), originating from the salivary gland of a lizard, Heloderma suspectum [13,14]. Ex-4 had 53% structural similarity with GLP-1 but could activate GLP-1 receptors (GLP-1R), and its longevity in the plasma was longer than that of GLP-1 [15]. This was due to a second amino acid of glycine rather than alanine, which imparted resistance to DPP-4 [15]. Ex-4 was used in clinical trials and approved in 2005 under the name Byetta as the first GLP-1RA for twice-daily treatment of type 2 diabetes mellitus (T2DM) [15,16]. Although these proteins were present for 2–3 hours longer in the plasma than the original GLP-1, they resulted in fluctuation of blood levels with once-daily or twice-daily administration [17].

Fig. 1.

Developmental timeline of GLP-1RAs. Dates for GLP-1 and exendin-4 are those of discovery. Dates for liraglutide and semaglutide are their approval dates for obesity. GLP-1, glucagon-like-peptide 1; GLP-1RA, GLP-1 receptor agonist; DPP4, dipeptidyl peptidase-4.

Development of long-lasting GLP-1 drugs

This prompted the development of new GLP-1RAs that could act longer, perhaps for weeks. Even though DPP-4 activity seemed to be the major issue for GLP-1 activity, a breakthrough came from another perspective when Lotte Knudsen from Novo Nordisk developed liraglutide [18]. To achieve a GLP-1RA that can act throughout the day, they made modifications and attached a fatty acid chain in the n-terminal that allows binding to albumin [19,20]. Albumin is abundantly produced from the liver and has multiple binding sites for fatty acids [21-23]. Being one of the most abundant proteins in the plasma, binding with albumin is usually not desirable for drugs because it makes the drugs remain in the body for an unwanted amount of time. However, Knudsen used albumin binding to retain GLP-1RA for as long as 11 hours in plasma [22]. Concurrently, it was becoming clear that T2DM and obesity had a very high correlation, and clinicians started to report a weight-loss effect of liraglutide in T2DM patients [24,25]. Soon, liraglutide was approved for both T2DM (Victoza, Novo Nordisk, Denmark) and obesity under the name of Saxenda (Novo Nordisk) for once-daily use [18,20]. Successful clinical trials and approval for these GLP-1 drugs led to an increase in GLP-1RAs, but once-daily use was still a barrier for some patients with diabetes or obesity because of the frequent use of needles for daily injections. This brought the need for a more convenient once-weekly applicable GLP-1RA drug. The remaining challenge was to change liraglutide to achieve a higher affinity toward GLP-1R even in the presence of albumin, since an improved affinity could accompany problems binding to GLP-1 [26]. Novo Nordisk addressed this and developed semaglutide by first changing the fatty chain acid linker to an "OEG" linker, which was observed to result in high receptor potency and high affinity for albumin [26]. Additionally, the peptide backbone at position 8 of liraglutide was changed from alanine to α-aminoisobutryic acid. In doing so, they kept the structure similar to that of the natural GLP-1 and also produced a new GLP-1RA resistant to DPP-4 [26]. These 2 changes allowed semaglutide durability for up to 1 week and resulted in U.S. Food and Drug Administration (FDA)-approved use for T2DM as the once-weekly drug Ozempic (Novo Nordisk) [27]. After the release of Ozempic, the interest in these drugs skyrocketed due to their high effectiveness in treating obesity, even though it is considered off-label use if not used for T2DM or cardiovascular diseases [28]. In 2021, the FDA approved semaglutide for chronic weight management in adults with obesity or overweight under the name Wegovy (Novo Nordisk) [29]. Due to the extensive amount of interest in these drugs, GLP-1 co-agonists are also being developed around the world to treat T2DM or obesity, and some show greater effects than Ozempic, Saxenda, or Wegovy [30,31].

Toward a comprehensive understanding of GLP-1 mechanisms in the body

Reflecting upon the explosive popularity of these drugs, investigations of the mechanism of GLP-1 and their uses in future clinical applications are being conducted. Clinical and preclinical studies are showing that GLP-1 extends beyond the original use in metabolic diseases to applications in drug addiction, neurodegenerative diseases, and inflammatory diseases [32-34]. This is probably due to the fact that GLP-1R is distributed both in the peripheral organs and in the central nervous system, the system that regulates most body functions [29]. Furthermore, GLP-1RA should not be understood to have the same mechanism as that of the endogenous GLP-1, as marketed GLP-1RAs function on a much longer timescale. Since the action of GLP-1 in the brain involves the activation of GLP-1R by GLP-1RAs to stimulate neuronal activity, it is essential to comprehensively understand the underlying mechanisms, including the signaling pathways and their corresponding neuronal responses. Therefore, in this review, we first cover the conventional signaling pathways of GLP-1 to understand their mechanisms in cells that regulate metabolism. We will then cover previous and recent findings of how GLP-1RA acts on GLP-1R neurons in the brain. Finally, we will discuss how these findings can relate to future applications for neuronal disorders and beyond.

GLP-1R signaling pathway in cells

In natural conditions, GLP-1 is produced by proteolytic cleavage of the protein proglucagon in a few body regions including the nucleus solitary tract (NTS) of the brainstem, enteroendocrine L cells, and the α cells of the pancreas [29,34,35]. GLP-1 functions by binding to GLP-1R, which is largely distributed throughout the peripheral and various regions in the brain [35,36]. In the peripheral, GLP-1R is distributed in the heart, pancreas, kidney, lung, and gastrointestinal (GI) tract. In the brain, it is distributed in the hypothalamic regions of the arcuate nucleus (ARC), dorsomedial hypothalamus (DMH), ventromedial hypothalamus (VMH), paraventricular hypothalamus (PVH), lateral hypothalamus (LH), and the subfornical organ; as well as in the brainstem regions of NTS, area postrema (AP), and dorsal vagal complex; and limbic system regions of the nucleus accumbens (NAc), ventral tegmental area (VTA), central amygdala (CeA), lateral septum (LS), hippocampus (HP), caudate putamen, globus pallidum, and other regions [37,38]. When GLP-1 reaches these regions, it binds to GLP-1R to produce a signaling cascade of the g-protein coupled receptor (GPCR) pathway. GLP-1R is a B-class GPCR that acts on both Gq and Gs signaling, comparable to the other incretin hormone glucose-dependent insulinotropic polypeptides (GIPs), though they only activate the Gs signaling pathway. Although the signaling pathways for pancreatic α, β, and δ cells are different as each cell type ultimately secretes different neuropeptides, they share similar cAMP-PKA pathways [29]. Gq/Gs signaling stimulates adenylate cyclase and increases cyclic AMP (cAMP) levels [39], which activates protein kinase A (PKA)-dependent intracellular signaling to stimulate different cascading pathways in different cells. The pathways modulate secretion of glucagon in α cells by regulating K-ATP channels, of insulin in β cells by regulating the PI3K/Akt signaling pathway, and of somatostatin in δ cells [2,29,40,41]. Inhibition of glucagon release by inhibition of α cell activity ultimately prevents an increase in the blood level, while β cell activation induces insulin release to lower blood levels. In addition, an increase of somatostatin by δ cells increases the activity of GI motility, reducing the secretion of glucagon from α cells and promoting insulin release from β cells [34]. In neurons, cAMP and PKA signaling pathways regulate synaptic plasticity by regulating pathways related to N-Methyl-D-aspartic acid (NMDA) and aminomethylphosphonic acid receptor signaling such as calcium influx into intracellular membranes to change synaptic plasticity for long-term potentiation related to memory function [42-45]. Indeed, GLP-1 was able to change synaptic plasticity in the PVH [46], hippocampus [47], LS [48], and the DMH [49,50]. In addition, co-treatment of obese mice with GLP-1RA and an NMDA receptor antagonist can induce greater change compared to GLP-1RA alone [51].

Activity of GLP-1R neurons in the brain

As stated above, GLP-1 modulates signal pathways in cells to induce changes in metabolism and neurophysiology. Recently, the role of GLP-1R neurons in feeding behaviors and neuropathology has been elucidated. Clinical studies have shown that the major effects of GLP-1RA in humans are regulation of blood levels or gut motility. Humans also report increased satiation and side effects such as nausea or vomiting [4]. These behaviors are modulated by regions in the brain such as the hypothalamus, hindbrain, and other areas near the circumventricular organ (CVO) that contain GLP-1R neurons [36].

One of the first studies that delivered GLP-1 into the brain was published in 1995, and showed that injection of intracerebroventricular (ICV) GLP-1 into hypothalamic regions reduced feeding and increased c-fos activity in the PVH and CeA [52]. Later studies delivered GLP-1 to specific regions in the hypothalamus and observed decreased feeding behaviors. Micro ICV injection of GLP-1 into the LH, a region associated with reward-related behaviors, decreased lever pressing in operant conditioning reward reinforcement tasks and showed decreased food intake and body weight [53]. ICV injection of GLP-1 into the VMH also induced anorexia and glucose tolerance [54]. Importantly, GLP-1 injection into the ARC was shown to decrease the activity of agouti-related peptide (AgRP) neurons and their strong orexigenic effect and to activate the pro-opiomelanincortin (POMC) neurons, which are prominent in satiety via melanocortin pathways [50,55,56]. AgRP and POMC neurons have reciprocal mechanisms; active AgRP neurons evoke hunger and inhibit POMC neurons, while POMC neurons activate satiety and inhibit AgRP neurons [57]. GLP-1R is not expressed in AgRP neurons but is expressed in POMC neurons [55], indicating that its effect on AgRP neurons is indirect and originates from other regions [50,55,56]. Recent studies have shown that GLP-1R also exists in the DMH while co-expressing leptin receptors (LepR) [58]. Furthermore, DMH LepR neurons respond to sensory information and send inhibitory projections to AgRP neurons, contributing to a decrease in anticipatory hunger caused by AgRP neurons [57,59,60]. This suggests that GLP-1 could send anticipatory signals of inhibited hunger via DMH GLP-1R neurons. Recently, we showed that GLP-1RA regulates AgRP neurons via DMH GLP-1R neurons to cause pre-ingestive satiation to control eating behavior [61] (Fig. 2). Other studies also highlighted the crucial role of DMH GLP-1R neurons in metabolism [49,62]. Although there has been some debate as to how the GLP-1R neurons in the hypothalamus are activated by GLP-1RA (when administered intraperitoneally), GLP-1 itself is degraded in the plasma in few minutes.

Fig. 2.

Mechanism of GLP-1RA activity in the brain. GLP-1RA travels to the brain by CVOs and to neighboring regions of the BBB. Regions in the brain that are colored blue indicate regions close to the CVO, while green indicates regions relatively far from the CVO. Red words indicate the effect of GLP-1RA in the brain or the effects of receptors. Arcuate nucleus of the hypothalamus (ARC), dorsomedial hypothalamus (DMH), ventromedial hypothalamus (VMH), paraventricular hypothalamus (PVH), lateral hypothalamus (LH), and the subfornical organ (SFO). Brainstem regions: nucleus tractus solitarius (NTS), area postrema (AP), dorsal vagal complex (DVC). Limbic system areas: nucleus accumbens (NAc), ventral tegmental area (VTA), central amygdala (CeA), lateral septum (LS), hippocampus (HP), and circumventricular organs (CVOs). GLP-1R, glucagon-like-peptide 1 receptor; GLP-1RA, GLP-1 receptor agonist; ATP, adenosine triphosphate; cAMP, cyclic AMP; PKA, protein kinase A.

The blood-brain barrier (BBB) is a major obstacle for drug entry into the brain. It is thought that GLP-1RA enters the hypothalamus through the third ventricle from circulation in the CVO by binding to tanycytes near the third ventricle [63]. The type of GLP-1RA affects the ability to cross the BBB [64]. Ex-4 is high in lipophilicity but is needed in high doses for penetration into the BBB [65]. Fluorescent-tagged Ex-4 has also been reported in regions deeper than the hypothalamus such as the VTA or the NAc, known for their primary role in reward processing [66,67]. Fluorescent-tagged liraglutide and semaglutide have also been shown to penetrate the hypothalamus and hindbrain but not further to the limbic systems [55,68]. These results show that the hypothalamus has essential roles in GLP-1RA-induced regulation of feeding behaviors, specifically by controlling meal termination.

Studies have also revealed the role of GLP-1RA in modulating the hindbrain for controlling feeding behavior. The hindbrain receives satiety signals from the body via GLP-1R and preproglucagon (PPG) neurons that express the gene gcg, which sends endogenous GLP-1 throughout the brain [69]. One of the regions that is most vulnerable to GLP-1 is the AP of the hindbrain ,which is located outside the BBB [70]. Administering GLP-1 ICV into the hindbrain reduced feeding [71] and increased nausea [72]. GLP-1R exists both in the AP, a region mainly known to cause nausea [72] and the NTS, a region mainly known to cause satiation effects [73]. Although it was difficult to determine the role of GLP-1R in either AP or NTS due to the spread of GLP-1RA drugs, a recent study elucidated the separate role of AP GLP-1R neurons and NTS GLP-1R neurons to encode aversion and satiation, respectively [74]. Furthermore, the study showed that AP GLP-1R neurons were not required for reducing food intake, while NTS GLP-1R neurons could evoke satiation without aversive effects, highlighting future directions for a non-aversive GLP-1R drug [74] (Fig. 2). Studies have also shown that AP GLP-1R neurons do not project to NTS PPG neurons, and NTS PPG neurons are not required for the effect of GLP-1RA [75]. These results show that GLP-1RA action on the hindbrain can be thought of as an independent effect from the endogenous GLP-1 activity induced by NTS PPG neurons. The role of endogenous GLP-1 signaling by NTS PPG neurons is currently under investigation. Studies have shown that activation of these neurons increases anorexia [76]; projects to form synapses with the PVN, a major controller of satiety [46,57]; and projects to the DMH to control glucose metabolism [49]. As NTS PPG neurons send multiple projections to other regions related to feeding, such as the ARC, CeA, and VMH, the mechanism of these circuits in controlling appetite suppression should be elucidated [75].

The roles of GLP-1R neurons in other regions of the brain are also being elucidated. A recent study has shown that active GLP-1RA neurons in the LS suppress feeding [48]. Interestingly, these neurons were deactivated during consumption, comparable with the activation of DMH GLP-1R neurons during consumption to encode pre-ingestive satiation [48,61]. These studies imply a complex network of GLP-1RA mechanisms in the brain. Other studies have shown that ICV delivery of GLP-1 into the CeA can evoke conditioned taste aversion, and the electrophysiological properties of these neurons have been investigated [77,78]. Systemic injection of Ex-4 was also able to evoke reduced cocaine seeking by activating GLP-1R in the NAc and the VTA [66,67]. Increased activity of HP GLP-1R neurons followed by Ex-4 injection reduced food intake, possibly due to volume transmission from NTS PPG neurons [79].

Collectively, these results imply that the action of GLP-1R induced by GLP-1RAs cannot be attributed to one specific region of the brain but must be understood from a brain-wide perspective. Modulating specific GLP-1R neurons in the brain might potentially enable control of certain aspects of feeding behavior, such as pre-ingestive satiation or non-aversive satiation.

Recent advancements in GLP-1RAs

The success of GLP-1 drugs has been mostly based on long-acting mono-agonists such as liraglutide and semaglutide. A randomized clinical trial comparing the effect of once-daily treatment of liraglutide and once-weekly treatment of semaglutide showed that adult patients treated with semaglutide for 68 weeks showed more than twice the decrease in body weight compared to people treated with liraglutide [80]. Furthermore, compared to liraglutide, semaglutide had fewer cases of side effects such as nausea, vomiting, diarrhea, and constipation [81]. Although both are GLP-1-based agonists, these 2 drugs have different effects on body weight and side effects.

Studies have further shown that greater body weight-loss effects can be achieved by combining GLP-1RA with other ligands as dual agonists. One of the first studies that confirmed the efficacy of GLP-1 dual agonism was on the synergetic effects of GLP-1 and GIP. Preclinical studies have shown that dual agonism of GIP and GLP-1RA could have a synergetic insulinotropic and glucose-lowering effect on beta cells in the pancreas [82]. We have further shown that this effect could originate from the hypothalamus, as a dual agonist of GLP-1RA with GIP had a synergetic effect in decreasing feeding behavior compared to GLP-1 or GIP alone when delivered to the hypothalamus in an ICV manner [83]. Recent studies have shown a strong effect of tirzepatide in inhibiting activity of AgRP neurons [84]. Notably, the effects of GIP on AgRP neurons were focused in nutrient response, while GLP-1R had an effect on response to sensory cues for food [84]. These GLP-RA and GIP dual agonists were approved by the U.S. FDA in November 2023 under the name Mounjaro, which shows a much larger body weight decrease than semaglutide and similar side effects [81,85].

Studies are further developing novel dual agonists to mitigate the side effects of mono-GLP-1RA or provide synergetic effects by stimulating other signaling pathways. A recent study developed a new dual agonist combination of semaglutide and MK-801 (an NMDA antagonist-based antidepressant) to mitigate the known yo-yo effect of GLP-1RA [51]. This study considered the limited ability of semaglutide to penetrate regions deeper than the hypothalamus and the internalization of GLP-1RA with binding to GLP-1R. They showed that MK-801 was cleaved after internalization in neurons, limiting its effect on synaptic plasticity to only GLP-1R neurons in the hypothalamus. Although the effects of these drugs were studied only for 2 weeks, they produced an average 20% body weight decrease, twice the effect of semaglutide alone. Furthermore, they confirmed that these drugs could change the expression levels of RNA related to synaptic plasticity, suggesting that the yo-yo effect could be mitigated by a change in long-term potentiation in hypothalamic neural circuitries [51]. Another study described a dual agonist to stimulate DMH neurons that co-express GLP-1R and LepR for decreased feeding behavior. This study further confirmed the validity of this effect in non-human primates, which shows that these dual agonists have high potential of success in humans [86]. Other studies have shown that GLP-1RA with melanocortin-4-receptor (MC4R) has a synergetic effect on body weight decrease [87,88].

As leptin-based drugs or MC4R agonist drugs alone have a limited effect on obesity, the co-agonists might treat broader conditions in obesity with better effects than mono-agonists. In combination with state-of-the-art technologies in neuroscience, recent studies are elucidating the impact of the mechanisms of synergetic compounds in neurons to shed light on the mechanism of GLP-1 co-agonists [84,89-91].

Another major point in the advancements of the usage of GLP-1 is its use in adolescents. This is important as metabolism rates such as total daily energy expenditure are greatly increased in children compared to adults [92]. Recent studies report that youths with obesity or T2DM (age<18 years) treated with lirglutide or semaglutide along with lifestyle interventions have better metabolic levels and experience greater body weight loss when treated with GLP-1 drugs but showed primary side effects such as nausea and vomiting [93-95]. Interestingly, the number of youths in the United States who was prescribed GLP-1RA increased from approximately 8,722 to 60,567 (594.4%) (ages 12–25 years) from January 2020 to December 2023, with most of this population being female (about 70%) [96]. The female preponderance may be because females are more prone to be interested in their weight. One preclinical study showed that exendin-4 injection in prenatal mice had no effect on body weight but did impact behaviors related to locomotion or anxiety but not learning [97]. Further studies are necessary to verify the impact of GLP-1RA treatment in early life, including effects on development, long-term consequences, and usage in adolescents younger than 12 years.

Future applications beyond obesity

As noted above, GLP-1RA affects cells in various organs in the peripheral through cAMP signaling pathways, changing activity in neurons that have GLP-1R. Their effect in the body varies depending on the drug used. To date, preclinical and clinical studies are reporting various uses for GLP-1 medicines [33]. Studies have shown that GLP-1 can be used for treatment of cardiac diseases, possibly independent of their effect in obesity [33] (Fig. 3). Furthermore, GLP-1 drugs have also been shown to affect inflammation in the heart, kidney, and liver [98,99]. Their effectiveness in addressing inflammation might be the reason for GLP-1RA effects in neurodegenerative diseases [100,101]. Investigation is ongoing to validate their effects in neurodegenerative diseases in preclinical and clinical trials [102]. As briefly mentioned above, GLP-1RA also affects drug addiction. Ex-4 can penetrate deep into the limbic system [66,67], well-known for its role in drug addiction due to changes in synaptic plasticity [103]. Furthermore, GLP-1RAs have been reported to modulate synaptic plasticity in neurons, which shows the possibility of using these drugs as a drug addiction treatment [45]. Indeed, clinical studies have shown such effects of GLP-1RA [104,105]. Given the eminent global opioid crisis, development of GLP-1RA is an important research goal [106].

Fig. 3.

Potential applications and development of GLP-1 drugs. GLP-1, glucagon-like-peptide 1; NTS, nucleus tractus solitarius; DMH, dorsomedial hypothalamus; VTA, ventral tegmental area; NAc, nucleus accumbens.

Conclusion

The future looks bright for GLP-1-based disease treatment. Given the large body of literature on GLP-1 mechanisms ranging from endocrinology to neuroscience and corresponding preclinical and clinical data, GLP-1-based treatment could offer a new pathway for treatment in diverse fields.

Notes

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

This work was supported by the National Research Foundation of Korea (NRF) (No. RS-2024-00406774, to KSK) and by a Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Ministry of Health & Welfare, Republic of Korea (No. RS-2024-00404132, RS-2024-00440099, to HJC).

Acknowledgments

We thank the members of the FNMR Lab for valuable discussions. Figure images were produced using Biorender.

Author contribution

Conceptualization: KSK, JSP, HJC; Data curation: KSK, JSP; Funding acquisition: KSK, HJC; Project administration: KSK, HJC; Visualization: KSK; Writing - original draft: KSK; Writing - review & editing: KSK, JSP, HJC

References

1. Drucker DJ. The GLP-1 journey: from discovery science to therapeutic impact. J Clin Invest 2024;134e175634.

2. Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest 2017;127:4217–27.

3. Lund P, Goodman R, Habener J. Pancreatic pre-proglucagons are encoded by two separate mRNAs. J Biol Chem 1981;256:6515–8.

4. Hayes MR, Borner T, De Jonghe BC. The role of GIP in the regulation of GLP-1 satiety and nausea. Diabetes 2021;70:1956–61.

5. Steiner DF. The proprotein convertases. Curr Opin Chem Biol 1998;2:31–9.

6. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409–39.

7. Dai C, Hang Y, Shostak A, Poffenberger G, Hart N, Prasad N, et al. Age-dependent human β cell proliferation induced by glucagon-like peptide 1 and calcineurin signaling. J Clin Invest 2017;127:3835–44.

8. Sonne DP, Rehfeld JF, Holst JJ, Vilsbøll T, Knop FK. Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1. Eur J Endocrinol 2014;171:407–19.

9. Deacon C. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004;36:761–5.

10. Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide. Histochemie 1966;7:197–201.

11. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999;85:9–24.

12. Ahrén B, Schmitz O. GLP-1 Receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004;36:867–76.

13. Eng J, Kleinman WA, Singh L, Singh G, Raufman J. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402–5.

14. Chen YE, Drucker DJ. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 1997;272:4108–15.

15. Bhavsar S, Mudaliar S, Cherrington A. Evolution of exenatide as a diabetes therapeutic. Curr Diabetes Rev 2013;9:161–93.

16. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696–705.

17. Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol 2018;14:390–403.

18. Nordisk N. Victoza package insert. Princeton (NJ): Novo Nordisk, 2013.

19. Greig SL, Scott LJ. Insulin degludec/liraglutide: a review in type 2 diabetes. Drugs 2015;75:1523–34.

20. Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract 2017;3:3–14.

21. Dharmalingam M, Sriram U, Baruah MP. Liraglutide: a review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. Indian J Endocrinol Metab 2011;15:9–17.

22. Knudsen LB. Inventing liraglutide, a glucagon-like peptide-1 analogue, for the treatment of diabetes and obesity. ACS Pharmacol Transl Sci 2019;2:468–84.

23. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000;43:1664–9.

24. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606–16.

25. Pi-Sunyer FX. The Effects of Pharmacologic agents for type 2 diabetes mellitus on body weight. Postgrad Med 2008;120:5–17.

26. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne) 2019;10:155.

27. Dhillon S. Semaglutide: first global approval. Drugs 2018;78:275–84.

28. Ashraf AR, Mackey TK, Vida RG, Kulcsár G, Schmidt J, Balázs O, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription: market surveillance, content analysis, and product purchase evaluation study. J Med Internet Res 2024;26e65440.

29. Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther 2024;9:234.

30. Ciardullo S, Morieri ML, Daniele G, Fiorentino TV, Mezza T, Tricò D, et al. GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes. Acta Diabetol 2024;61:941–50.

31. Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. eClinicalMedicine 2024;75:102782.

32. Drucker DJ. Expanding applications of therapies based on GLP1. Nat Rev Endocrinol 2025;21:65–6.

33. Drucker DJ. The benefits of GLP-1 drugs beyond obesity. Science 2024;385:258–60.

34. Wilbon SS, Kolonin MG. GLP1 receptor agonists-effects beyond obesity and diabetes. Cells 2023;13:65.

35. Smith NK, Hackett TA, Galli A, Flynn CR. GLP-1: molecular mechanisms and outcomes of a complex signaling system. Neurochem Int 2019;128:94–105.

36. Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest 2014;124:4223–6.

37. Alvarez E, Martínez MD, Roncero I, Chowen JA, García-Cuartero B, Gispert JD, et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 2005;92:798–806.

38. Richards P, Parker HE, Adriaenssens AE, Hodgson JM, Cork SC, Trapp S, et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 2014;63:1224–33.

39. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987;84:3434–8.

40. Yang H, Yang L. Targeting cAMP/PKA pathway for glycemic control and type 2 diabetes therapy. J Mol Endocrinol 2016;57:R93–108.

41. Hameed A, Hafizur RM, Hussain N, Raza SA, Rehman M, Ashraf S, et al. Eriodictyol stimulates insulin secretion through cAMP/PKA signaling pathway in mice islets. Eur J Pharmacol 2018;820:245–55.

42. Diz-Chaves Y, Mastoor Z, Spuch C, González-Matías L, Mallo F. Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases. Int J Mol Sci 2022;23:9583.

43. Chen XY, Chen L, Yang W, Xie A-M. GLP-1 Suppresses feeding behaviors and modulates neuronal electrophysiological properties in multiple brain regions. Front Mol Neurosci 2021;14:793004.

44. Abel T, Nguyen P. Chapter 6 regulation of hippocampus-dependent memory by cyclic AMP-dependent protein kinase. Prog Brain Res 2008;169:97–115.

45. Liu J, Pang ZP. Glucagon-like peptide-1 drives energy metabolism on the synaptic highway. FEBS J 2016;283:4413–23.

46. Liu J, Conde K, Zhang P, Lilascharoen V, Xu Z, Lim BK, et al. Enhanced AMPA receptor trafficking mediates the anorexigenic effect of endogenous glucagon-like peptide-1 in the paraventricular hypothalamus. Neuron 2017;96:897–909.e5.

47. Oka JI, Goto N, Kameyama T. Glucagon-like peptide-1 modulates neuronal activity in the rat's hippocampus. Neuroreport 1999;10:1643–6.

48. Chen Z, Deng X, Shi C, Jing H, Tian Y, Zhong J, et al. GLP-1R-positive neurons in the lateral septum mediate the anorectic and weight-lowering effects of liraglutide in mice. J Clin Invest 2024;134e178239.

49. Huang Z, Liu L, Zhang J, Conde K, Phansalkar J, Li Z, et al. Glucose-sensing glucagon-like peptide-1 receptor neurons in the dorsomedial hypothalamus regulate glucose metabolism. Sci Adv 2022;8:eabn5345.

50. Dong Y, Carty J, Goldstein N, He Z, Hwang E, Chau D, et al. Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo. Mol Metab 2021;54:101352.

51. Petersen J, Ludwig MQ, Juozaityte V, Ranea-Robles P, Svendsen C, Hwang E, et al. GLP-1-directed NMDA receptor antagonism for obesity treatment. Nature 2024;629:1133–41.

52. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69–72.

53. López-Ferreras L, Richard JE, Noble EE, Eerola K, Anderberg RH, Olandersson K, et al. Lateral hypothalamic GLP-1 receptors are critical for the control of food reinforcement, ingestive behavior and body weight. Mol Psychiatry 2018;23:1157–68.

54. Burmeister MA, Brown JD, Ayala JE, Stoffers DA, Sandoval DA, Seeley RJ, et al. The glucagon-like peptide-1 receptor in the ventromedial hypothalamus reduces short-term food intake in male mice by regulating nutrient sensor activity. Am J Physiol Endocrinol Metab 2017;313:E651–62.

55. Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014;124:4473–88.

56. He Z, Gao Y, Lieu L, Afrin S, Cao J, Michael NJ, et al. Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons - Implications for energy balance and glucose control. Mol Metab 2019;28:120–34.

57. Andermann ML, Lowell BB. Toward a wiring diagram understanding of appetite control. Neuron 2017;95:757–78.

58. Rupp AC, Tomlinson AJ, Affinati AH, Yacawych WT, Duensing AM, True C, et al. Suppression of food intake by Glp1r/Lepr-coexpressing neurons prevents obesity in mouse models. J Clin Invest 2023;133e157515.

59. Berrios J, Li C, Madara JC, Garfield AS, Steger JS, Krashes MJ, et al. Food cue regulation of AGRP hunger neurons guides learning. Nature 2021;595:695–700.

60. Garfield AS, Shah BP, Burgess CR, Li MM, Li C, Steger JS, et al. Dynamic GABAergic afferent modulation of AgRP neurons. Nat Neurosci 2016;19:1628–35.

61. Kim KS, Park JS, Hwang E, Park MJ, Shin HY, Lee YH, et al. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans. Science 2024;385:438–46.

62. Lee SJ, Sanchez-Watts G, Krieger JP, Pignalosa A, Norell PN, Cortella A, et al. Loss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity. Mol Metab 2018;11:33–46.

63. Imbernon M, Saponaro C, Helms HC, Duquenne M, Fernandois D, Deligia E, et al. Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions. Cell Metab 2022;34:1054–63.e7.

64. Cao Y, Tong Q. Hunting for heroes: Brain neurons mediating GLP-1R agonists in obesity treatment. Obes Med 2024;52:100569.

65. Kastin A, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes 2003;27:313–8.

66. Hernandez NS, Ige KY, Mietlicki-Baase EG, Molina-Castro GC, Turner CA, Hayes MR, et al. Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats. Neuropsychopharmacology 2018;43:2000–8.

67. Hernandez NS, O'Donovan B, Ortinski PI, Schmidt HD. Activation of glucagon-like peptide-1 receptors in the nucleus accumbens attenuates cocaine seeking in rats. Addict Biol 2019;24:170–81.

68. Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 2020;5:133429.

69. Daniels D, Mietlicki-Baase EG. Glucagon-like peptide 1 in the brain: where is it coming from, where is it going? Diabetes 2018;68:15–7.

70. Price CJ, Hoyda TD, Ferguson AV. The area postrema: a brain monitor and integrator of systemic autonomic state. Neuroscientist 2008;14:182–94.

71. Hayes MR, Skibicka KP, Grill HJ. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 2008;149:4059–68.

72. Zhang C, Kaye JA, Cai Z, Wang Y, Prescott SL, Liberles SD. Area postrema cell types that mediate nausea-associated behaviors. Neuron 2021;109:461–72.e5.

73. Ly T, Oh JY, Sivakumar N, Shehata S, La Santa Medina N, Huang H, et al. Sequential appetite suppression by oral and visceral feedback to the brainstem. Nature 2023;624:130–7.

74. Huang KP, Acosta AA, Ghidewon MY, McKnight AD, Almeida MS, Nyema NT, et al. Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature 2024;632:585–93.

75. Brierley DI, Holt MK, Singh A, de Araujo A, McDougle M, Vergara M, et al. Central and peripheral GLP-1 systems independently suppress eating. Nat Metab 2021;3:258–73.

76. Gaykema RP, Newmyer BA, Ottolini M, Raje V, Warthen DM, Lambeth PS, et al. Activation of murine preproglucagon-producing neurons reduces food intake and body weight. J Clin Invest 2017;127:1031–45.

77. Kinzig KP, D'Alessio DA, Herman JP, Sakai RR, Vahl TP, Figueiredo HF, et al. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 2003;23:6163–70.

78. Zeng N, Cutts EJ, Lopez CB, Kaur S, Duran M, Virkus SA, et al. Anatomical and functional characterization of central amygdala glucagon-like peptide 1 receptor expressing neurons. Front Behav Neurosci 2021;15:724030.

79. Hsu TM, Hahn JD, Konanur VR, Lam A, Kanoski SE. Hippocampal GLP-1 receptors influence food intake, meal size, and effort-based responding for food through volume transmission. Neuropsychopharmacology 2015;40:327–37.

80. Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 2022;327:138–50.

81. Ghusn W, Hurtado MD. Glucagon-like Receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks. Obes Pillars 2024;12:100127.

82. Gault VA, Kerr BD, Harriott P, Flatt PR. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with type 2 diabetes and obesity. Clin Sci 2011;121:107–17.

83. NamKoong C, Kim MS, Jang BT, Lee YH, Cho YM, Choi HJ. Central administration of GLP-1 and GIP decreases feeding in mice. Biochem Biophys Res Commun 2017;490:247–52.

84. McMorrow HE, Lorch CM, Hayes NW, Fleps SW, Frydman JA, Xia JL, et al. Incretin hormones and pharmacomimetics rapidly inhibit AgRP neuron activity to suppress appetite. bioRxiv [Preprint] 2024;Mar. 20. 2024.03.18.585583. doi: 10.1101/2024.03.18.585583.

85. Abbasi J. FDA Green-lights tirzepatide, marketed as zepbound, for chronic weight management. JAMA 2023;330:2143–4.

86. Polex-Wolf J, Deibler K, Hogendorf WFJ, Bau S, Glendorf T, Stidsen CE, et al. Glp1r-Lepr coexpressing neurons modulate the suppression of food intake and body weight by a GLP-1/leptin dual agonist. Sci Transl Med 2024;16eadk4908.

87. Clemmensen C, Finan B, Fischer K, Tom RZ, Legutko B, Sehrer L, et al. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice. EMBO Mol Med 2015;7:288–98.

88. Dahir NS, Gui Y, Wu Y, Sweeney PR, Rouault AA, Williams SY, et al. Subthreshold activation of the melanocortin system causes generalized sensitization to anorectic agents in mice. J Clin Invest 2024;134e178250.

89. Zhang SX, Kim A, Madara JC, Zhu PK, Christenson LF, Lutas A, et al. Stochastic neuropeptide signals compete to calibrate the rate of satiation. Nature 2025;637:137–44.

90. Cardozo Pinto DF, Pomrenze MB, Guo MY, Touponse GC, Chen APF, Bentzley BS, et al. Opponent control of reinforcement by striatal dopamine and serotonin. Nature 2025;639:143–52.

91. Kim DI, Park S, Park S, Ye M, Chen JY, Kang SJ, et al. Presynaptic sensor and silencer of peptidergic transmission reveal neuropeptides as primary transmitters in pontine fear circuit. Cell 2024;187:5102–17.e16.

92. Pontzer H, Yamada Y, Sagayama H, Ainslie PN, Andersen LF, Anderson LJ, et al. Daily energy expenditure through the human life course. Science 2021;373:808–12.

93. Yugar LB, Sedenho-Prado LG, da Silva Ferreira IM, Silva CA, Sposito AC, Cercato C. The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis. Diabetol Metab Syndr 2024;16:92.

94. Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med 2022;387:2245–57.

95. Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med 2020;382:2117–28.

96. Lee JM, Sharifi M, Oshman L, Griauzde DH, Chua KP. Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020-2023. JAMA 2024;331:2041–3.

97. Cerroni C, Steiner A, Seanez L, Kwon S, Lewis AS. Effects of repeated developmental GLP-1R agonist exposure on young adult behavior and hippocampal structure in mice. Neurosci Lett 2023;808:137299.

98. Wong CK, McLean BA, Baggio LL, Koehler JA, Hammoud R, Rittig N, et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metab 2024;36:130–43.e5.

99. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JF, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391:109–21.

100. Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017;390:1664–75.

101. Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, et al. Trial of lixisenatide in early Parkinson’s disease. N Engl J Med 2024;390:1176–85.

102. Forny Germano L, Koehler JA, Baggio LL, Cui F, Wong CK, Rittig N, et al. The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice. Mol Metab 2024;89:102019.

103. Lüscher C, Malenka RC. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 2011;69:650–63.

104. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with tobacco use disorder in patients with type 2 diabetes: target trial emulation using real-world data. Ann Intern Med 2024;177:1016–27.

105. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Mol Psychiatry 2024;29:2587–98.

106. Gottschalk M. The opioid crisis: the war on drugs is over. long live the war on drugs. Annu Rev Criminol 2023;6:363–98.

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.